USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
SK Holdings revealed its acquisition of a French drug-maker called Yposkesi this week. The third-largest conglomerate in South Korea made the purchase in its bid to strengthen its competitive power in the global market’s biotech sector.
Moreover, SK has acquired French drug manufacturer Yposkesi to expand into the rapidly growing contract manufacturing organization (CMO) business, the newly renamed holding company of SK Group said Wednesday.
SK completed the acquisition
The Korea Times reported that SK acquired 70% percent shares, and this includes management rights in the French company. The acquisition came four months after the South Korean company said it is in talks to purchase Yposkesi.
The price of the deal was not mentioned in the reports, so there is no clear figure how much SK shelled out for the acquisition. The deal has been completed, and Yposkesi will now be operated by SK Pharmteco, a CMO subsidiary owned by SK Inc. based in Sacramento.
"We are glad to advance into the gene therapy CMO business by investing in Yposkesi which has great capability and potential," Jang Dong Kyun, SK’s chief executive officer, said. "We will spare no efforts to help Yposkesi grow fast in the global market."
About Yposkesi
Yposkesi, the French cell, and gene therapy company, is also one of the largest Contract Development & Manufacturing Organizations (CDMO) in Europe. With the purchase of this company, SK will now be able to supply innovative drugs around the world through creating a contract manufacturing organization (CMO) business system, as per Aju Business Daily.
Yposkesi was launched in 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance. It is the first French firm to develop and produce gene and cell therapy products. The company’s goal is to create the first treatments available to patients then sell them for a fair price.
Meanwhile, this is SK Holding’s third acquisition deal in the global CMO industry as it aims to be one of the best players in the biotechnology industry. Its purchase of pharma and biotech companies shows its determination to rise above in the market for this field.
"SK plans to complete the value chain of its synthetic and biopharmaceutical CMO business in the U.S., Europe and Asia by 2025," SK’s head in bio investment center, Lee Dong Hoon, said. "We will foster SK Pharmteco as a global leading CMO that can supply synthetic, gene and cell therapy drugs to the global pharmaceutical market."
